Dominic Smethurst
Known title: Chief Medical OfficerCIK: 0001820549
Associated companies
Transaction History
| CRBP | ▼ Sell | Open Market | 6,097 | $51K | 3/2/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 3,285 | $27K | 2/3/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 28,365 | $0 | 1/14/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 6,393 | $43K | 3/6/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 27,200 | $0 | 1/31/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 50,000 | $0 | 2/27/2024 | View on chart |
| BCYC | ▲ Buy | Grant | 17,500 | $0 | 1/3/2023 | View on chart |
| BCYC | ▼ Sell | Open Market | 1,801 | $52K | 1/3/2023 | View on chart |
| BCYC | ▲ Buy | Grant | 15,000 | $0 | 1/3/2022 | View on chart |
| BCYC | ▲ Buy | Option Exercise | 6,000 | $111K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.